Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
Criminal IP Reveals Global React2Shell RCE Exposure Across React Server Components
TORRANCE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- In December 2025, the…
Real-World Data Presented at TCT 2025 Demonstrates the EggNest Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team
SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ -- At the 2025 Transcatheter Cardiovascular…
FACT CHECK: Frequency Holdings YCRM Issues Clarification On Procedural Judgment; No Liability to Company, Litigation Exposure Remains for Luciano Aguayo
CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) -- Frequency Holdings Inc. (OTC: YCRM),…
